Healthcare can be complicated.
Your cardiology news shouldn’t be.
Join thousands of cardiology leaders today.
Population Health March 16, 2026
Where We’ve Been, and Where We’re Going in CV Health March 16, 2026
JACC released its inaugural Cardiovascular Statistics 2026 report covering a wide spectrum of major CV risk factors and conditions, and despite the medical advancements in the last […]
Cardiac Imaging March 12, 2026
IVI or Angiography for Complex PCI Guidance? March 12, 2026
New follow-up data from the RENOVATE-COMPLEX-PCI trial suggests that intravascular imaging continues to provide better clinical outcomes for patients with complex coronary lesions five years after their […]
Heart Failure March 9, 2026
Barostim Boosts QoL and LVEF, but Mortality Benefit Still Unknown March 9, 2026
Strong results from two separate studies on CVRx’s Barostim baroreflex activation therapy suggest the technology might offer symptomatic relief even though its mortality benefit is still up […]
Cardiology Testing March 5, 2026
What NT-proBNP Can Tell Us About TEER Outcomes March 5, 2026
New research presented at THT 2026 suggests that the NT-proBNP biomarker could give us a glimpse into which patients with severe tricuspid regurgitation (TR) will benefit the […]
More Stories
Cardiology Testing March 2, 2026
Two Cardiac Troponins Don’t Tell the Same Story March 2, 2026
There might be a bigger difference between the types of cardiac troponin assays, after a recent JACC analysis found that the type of troponin could help us […]
Cardiovascular Disease February 26, 2026
Women’s CVD Will Keep Rising by 2050 February 26, 2026
Imagine an America where two out of three women suffer from cardiovascular disease. What would it look like for your mother, sister, or daughter? The American Heart […]
Surgeries & Interventions February 23, 2026
Market Competition Drives TAVR Overutilization February 23, 2026
Whether or not a patient receives TAVR over SAVR might be more influenced by market forces than clinical evidence, after a recent study found that the more […]
Heart Failure February 19, 2026
Rethinking Hyperkalemia Care in Patients With Heart Failure February 19, 2026
By Ravi Dhingra, MD, MPH, FACC, FAHASponsored By AstraZeneca Renin-angiotensin-aldosterone system inhibitor (RAASi) therapy is a cornerstone of heart failure (HF) management, yet concerns about hyperkalemia (HK) […]
Surgeries & Interventions February 19, 2026
Evolut Low Risk, A Tale of Two Outcomes February 19, 2026
We might need to reconsider the concept of a TAVR-first strategy for low-risk aortic stenosis patients, after extended results from the Evolut Low Risk trial showed that […]
Cardiology Pharmaceuticals February 16, 2026
DAPT Drugs Matter to Diabetics with Multivessel CAD February 16, 2026
The debate over which dual antiplatelet therapy is best for diabetic CAD patients might favor generic prasugrel over ticagrelor (AstraZeneca’s Brilinta), after the TUXEDO-2 trial demonstrated that […]
Artificial Intelligence February 12, 2026
Google’s AMIE Shows Promise for Cardiology Care February 12, 2026
AI scribes and LLMs’ potential impact on cardiology just became a lot clearer after a Stanford RCT published in Nature Medicine demonstrated that Google’s AMIE system helped […]
Cardiology Pharmaceuticals February 9, 2026
Statin Side Effects Might Not be So Bad February 9, 2026
New research in The Lancet suggests that statin underutilization might stem from unfounded safety fears rather than actual risk, after researchers found that 62 out of 66 […]
Cardiology Business February 5, 2026
Medtronic Acquires CathWorks, Expands Cath Lab Presence February 5, 2026
Using AI algorithms to diagnose and assess coronary artery disease for intervention is about to become more mainstream after medtech giant, Medtronic, agreed to exercise its acquisition […]
Cardiology Pharmaceuticals February 2, 2026
CKM’s True Medication Burden February 2, 2026
As cardiology begins to look at the spectrum of cardiovascular-kidney-metabolic disease, new research in JAMA suggests that CKM treatments might face serious adoption challenges due to the […]
Heart Failure January 29, 2026
Telemedicine’s Unintended HF Consequences January 29, 2026
Heart failure telemedicine doesn’t seem to be lining up evidence-based care after a recent Stanford Medicine analysis revealed that remotely-managed HF patients received less diagnostic testing and […]
Heart Failure January 26, 2026
Advancing Heart Failure Care: Timely Referral and Life-prolonging Strategies with HeartMate 3 Left Ventricular Assist Device January 26, 2026
Excerpt from Article by Dr. Sanjeev Gulati, Radcliffe Cardiology 2025; e1. Heart failure (HF) remains a leading cause of morbidity and mortality globally, and advanced HF represents […]
Cardiology Policy January 26, 2026
Women Need Lower LV Thresholds for AV Surgery January 26, 2026
New multicenter data published in JAMA suggests that surgery for aortic regurgitation may need to be done earlier than current guidelines recommend, with lower LV size thresholds […]
Cardiac Imaging January 22, 2026
IVUS and OCT Better Than Angiography for PCI January 22, 2026
A recent JACC: Cardiovascular Interventions analysis of 17 randomized trials suggests that intravascular cardiac imaging (intravascular ultrasound or optical coherence tomography) significantly reduces major cardiac events compared […]
Cardiology Business January 15, 2026
FTC Wins Lawsuit Against Edwards Over JenaValve January 15, 2026
Following a six-month antitrust fight, Edwards Lifesciences has been forced to walk away from its $945M attempt to buy fledgling valve developer JenaValve after a U.S. district […]
Cardiogenetics January 12, 2026
Y Chromosome Loss and MI Risk January 12, 2026
We already know that loss or mutation in genes can lead to increased cardiovascular risk or even cause some diseases, but what about losing a whole chromosome? […]
Cardiology Testing January 8, 2026
HF Frailty Could Be Simpler than We Think January 8, 2026
A new registry analysis out of Japan suggests we may be able to simplify how we classify heart failure frailty without losing accuracy, allowing us to screen […]
Cardiology Pharmaceuticals January 5, 2026
Aficamten Approved, Enter a New HCM Contender January 5, 2026
After years of dedicated research and careful science, Cytokinetics’ aficamten (Myqorzo) is officially FDA approved for obstructive hypertrophic cardiomyopathy, marking the company’s first-ever regulatory approval and ending […]